

# NOTICE OF PUBLIC MEETING

State of Alaska  
Department of Health & Social Services  
Division of Health Care Services

The Division will be sponsoring the following meeting to address the Preferred Drug List.

The Medicaid Pharmacy & Therapeutics Committee will meet Friday, April 20, 2012 from 8 AM to 12:00 PM and will be held at the Frontier Building, 3601 "C" Street; Room 890/896, Anchorage, Alaska.

The public is invited to attend this meeting and give public comment. If you are unable to attend in person, you may join via teleconference by calling: 1-800-315-6338. Use access code 735#. Time will be allowed for public comment during the meeting. For information on making public comments to the Committee, or to obtain an agenda please dial (907) 334-2654.

Three sets of classes are up for review. **RED & BLUE CLASSES** – PUBLIC TESTIMONY WILL BE TAKEN ONLY IF **\*\*\*NEW INFORMATION\*\*\*** IS RECEIVED. **GREEN CLASS** – No changes are recommended and no public testimony will be taken.

### **\*\*\*NEW INFORMATION\*\*\***

**Includes new drugs or indications, new warnings or new head to head clinical evidence**

#### **RED CLASS Drug List – For new classes or classes where new information exists:**

Re-Review Long Acting Beta Agonists	Re-Review Hepatitis C
*Review Ophthalmic Antibiotic-Steroid Combo	Re-Review Ophthalmic NSAIDS (now contains Zolasses)
Re-Review COPD Inhalant Drugs	

#### **BLUE CLASS Drug List – Will be reviewed only if new information is received:**

Re-Review Ophthalmic Anti-Allergy Agents	Re-Review Topical Antivirals
Re-Review Ophthalmic Mast Cell Stabilizers	Re-Review Hepatitis B - Oral
Re-Review Otic Quinolones <> Otic Antibiotics	Re-Review Topical Antifungals
Re-Review Inhaled Steroids <> Glucocorticoid Inhaled	

#### **GREEN CLASS Drug List – No changes are recommended and no public testimony will be taken:**

Re-Review Self Injectable Epinephrine	Re-Review Anti-Emetics
Re-Review Intranasal Antihistamines	Re-Review Leukotriene Inhibitors
Re-Review Nasal Steroids	Re-Review Short Acting Beta Agonists
Re-Review Low-Sedating Antihistamines	
Re-Review Ophthalmic Quinolones <> Ophthalmic Antibiotics	Re-Review Ophthalmic Immunomodulator
Re-Review Ophthalmic Macrolides <> Ophthalmic Antibiotics	Re-Review Anti-Herpes Oral Medication <> Antivirals HSV
Re-Review 2nd & 3rd Generation Cephalosporins	Re-Review Anti-Fungal - Oral
Re-Review 2nd & 3rd Generation Quinolones	Re-Review Anti-viral - Influenza
Re-Review Macrolides	Re-Review Topical Antibiotics
Re-Review Anti-Migraines	

Clinical information for dissemination to the Pharmacy & Therapeutics Committee needs to be sent by March 20, 2012 to Magellen Medicaid Administration, Fax: 1-888-656-6822, Attention: Julie Pritchard, PharmD, MBA.

See Clinical Submission Form at [http://hss.state.ak.us/dhcs/PDL/download\\_pdl.htm](http://hss.state.ak.us/dhcs/PDL/download_pdl.htm)

Individuals with disabilities who need special accommodations in order to participate should call (907) 334-2654 no later than 2:00 p.m., Thursday, April 19, 2012.